- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04219319
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patiens
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Oncology Department,The First Affiliated Hospital of USTC west district
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Hematological Department, People's Hospital of Jiangsu Province
-
-
Shanxi
-
Xi'an, Shanxi, China, 710032
- Hematological Department,The First Affiliated Hospital of the Air Force Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent form (ICF)
- Age 18 Years to 75 Years
Pathological diagnosis of refractory/relapsed CD4+ T lymphocyte tumor (one of the following):
- T-cell Non-Hodgkin lymphoma(T-NHL):The best response is progressive disease(PD) or stable disease(SD) after at least 1 prior line of therapy(at least 2 complete cycle of therapy)
- T-cell Acute lymphoblastic leukemia(T-ALL):The best response is not complete response(CR) after induction therapy
- Measurable disease is necessary at Screening
- Life expectancy ≥ 3 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 -2.
- The screening phase clinical laboratory values meet the following criteria. Laboratory test(s) may be repeated once, to determine if the subject qualifies for study participation :
Blood routine:
HGB≥6g/dL;PLT≥20×10^9/L; ANC≥1.0×10^9/L; LY≥0.3×10^9/L
Blood biochemical parameters:
- Aspartate and alanine aminotransferases (AST, ALT) ≤ 2.5 times ULN (in the presence of liver metastasis, AST and ALT≤5 times ULN)
- Serum creatinine (Scr) ≤ 1.5 times ULN, estimated glomerular filtration rate (eGFR) > 60mL/min (only when Scr>1.5 times ULN)
- Total bilirubin ≤ 1.5 times of the normal upper limit (ULN)
- International Normalized Ratio (INR) ≤ 1.5 times ULN, PT≤ 1.5 times ULN, APTT≤ 1.5 times ULN
Exclusion Criteria:
- Prior treatment with CAR-T therapy directed at any target.
- Any therapy that is targeted to CD4.
- Prior treatment with an allogeneic stem cell transplant
Any malignancy besides the T lymphocyte tumor categories under study, exceptions include
- Any other malignancy curatively treated and disease-free for at least 2 years prior to enrollment
- History of non-melanoma skin cancer with sufficient treatment and currently no evidence of recurrence
- Those who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab)
The following cardiac conditions:
- New York Heart Association (NYHA) stage III or IV congestive heart failure
- Myocardial infarction or coronary artery bypass graft (CABG) 6 months prior to enrollment
- History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
- History of severe non-ischemic cardiomyopathy
- Impaired cardiac function (LVEF <45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan (performed ≤8 weeks of apheresis)
Prior antitumor therapy as follows, prior to apheresis:
- Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is less.
- Monoclonal antibody treatment for multiple myeloma within 21 days.
- Cytotoxic therapy within 14 days.
- Radiotherapy within 14 days.
- Participated in other clinical trials within 30 days.
- Toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
- With central nervous system involvement.
Serious underlying medical condition, such as:
- Evidence of serious active viral, bacterial, or uncontrolled systemic fungal infection
- Active or unstable autoimmune diseases or autoimmune diseases that have been suffered within 3 years and have the possibility of recurrence
- Overt clinical evidence of dementia or altered mental status
- Pregnant or breast-feeding, or planning to become pregnant while enrolled in this study or within 100 days after receiving study treatment.
- Plans to father a child while enrolled in this study or within 100 days after receiving study treatment.
- With obvious hemorrhagic tendency such as gastrointestinal hemorrhage, coagulation disorders and hypersplenism
- Oxygen is needed to maintain sufficient blood oxygen saturation(≥95%)
- Suffer from chronic diseases that require treatment with systemic corticosteroids or other immunosuppressive agents ,Received a cumulative dose of corticosteroids equivalent to ≥20 mg/day of prednisone within 7 days prior to apheresis
- CNS diseases with clinical significance in the past or at the time of screening
- Vaccinated with live, attenuated vaccine within 4 weeks prior to apheresis
- Major surgery within 2 weeks prior to apheresis, or has surgery planned during the study or within 2 weeks after study treatment administration. (Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate.)
- Known life threatening allergies, hypersensitivity, or intolerance to LCAR-T2C CAR-T cells or its excipients, including DMSO (refer to Investigator's Brochure)
- Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor
An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
|
CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity (DLT)
Time Frame: 30 days post infusion
|
DLT assessed by NCI-CTCAE 5.0
|
30 days post infusion
|
Adverse events
Time Frame: 90 days post infusion
|
Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0
|
90 days post infusion
|
Recommended Phase II dose (RP2D)
Time Frame: 30 days post infusion
|
RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion
|
30 days post infusion
|
Pharmacokinetics
Time Frame: through study completion, 2 years after infusion of the last subject
|
PK CAR positive T cells in peripheral blood, PK CAR transgene levels in peripheral blood, PK CAR positive T cells in bone marrow and PK CAR transgene levels in bone marrow.
|
through study completion, 2 years after infusion of the last subject
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-drug antibody
Time Frame: through study completion, 2 years after infusion of the last subject
|
Anti-drug antibody (ADA) will be conducted on blood sample for immune response analyses.
|
through study completion, 2 years after infusion of the last subject
|
Overall response rate (ORR) after administration
Time Frame: through study completion, 2 years after infusion of the last subject
|
through study completion, 2 years after infusion of the last subject
|
|
Time to Response (TTR) after administration
Time Frame: through study completion, 2 years after infusion of the last subject
|
through study completion, 2 years after infusion of the last subject
|
|
Duration of remission (DOR) after administration
Time Frame: through study completion, 2 years after infusion of the last subject
|
through study completion, 2 years after infusion of the last subject
|
|
Progress Free Survival (PFS) after administration
Time Frame: through study completion, 2 years after infusion of the last subject
|
through study completion, 2 years after infusion of the last subject
|
|
Over Survival (OS) after administration
Time Frame: through study completion, 2 years after infusion of the last subject
|
through study completion, 2 years after infusion of the last subject
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guangxun Gao, PhD& MD, the First Affiliated Hospital of the Air Force Medical University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BM2L201905
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingT-cell Large Granular Lymphocyte Leukemia | T-cell Lymphomas | T-cell Prolymphocytic Leukemia | NK-Cell LymphomasUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditionsUnited States
-
Pierluigi PorcuMillennium Pharmaceuticals, Inc.; Celgene CorporationCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Post-transplant Lymphoproliferative Disorder | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedPeripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)United States
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
National Cancer Institute (NCI)WithdrawnHepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell LymphomaUnited States
-
Ohio State University Comprehensive Cancer CenterCelgene CorporationRecruitingCutaneous T-cell Lymphoma | Peripheral T-Cell Lymphoma | T-Prolymphocytic Leukemia | T-Large Granulocytic Leukemia | T-Lymphoblastic Leukemia/LymphomaUnited States
-
Washington University School of MedicineWugen, Inc.RecruitingAcute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditionsUnited States
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)Japan
-
Shanghai General Hospital, Shanghai Jiao Tong University...SuspendedAngioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | Anaplastic Lymphoma | Acute T Cell Leukemia | T-lymphoblastic LymphomaChina
Clinical Trials on Efficacy of LCAR-T2C CAR-T cells
-
Beijing Boren HospitalNanjing Legend Biotech Co.TerminatedT-cell Leukemia | T Cell LymphomaChina
-
Janssen Research & Development, LLCRecruitingMultiple MyelomaUnited States, Belgium, China, Israel, Netherlands, Spain, Japan
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.UnknownRefractory or Relapsed Multiple MyelomaChina
-
Nanjing Legend Biotech Co.Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaboratorsActive, not recruitingRefractory or Relapsed Multiple Myeloma
-
Nanjing Legend Biotech Co.Janssen Research & Development, LLCRecruiting
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma